We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.
More patient information
Find answers to some of your most frequently asked questions
New methods and reliable tests to help deliver personalised treatment
RGCC CAMBISeq (cancer analysis, mutational burden and instability sequencing) provides next generation sequencing analysis on both DNA and RNA to help predict a patient’s response to immunotherapy and to detect variants.
This test identifies chromosomal abnormalities – when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer. It uses a technique called array CGH to identify abnormalities in a genome more clearly than traditional microscopes can. These abnormalities could be linked with parts of regions […]
This test focuses on the status of a patient’s immune system. The test uses specific cellular markers, and the production of proteins called cytokines, to detect the type or types of cells that are responsible for switching a patient’s immune system on and off. Immune-Frame uses two different assays: the ELISA assay is used to […]
This test provides information, based on the detection of circulating tumour cells, about whether and where the tumour is likely to spread. Studies show that the cancer cells that have the potential to spread from the primary tumour express specific genes and proteins, or markers. These markers vary according to the organ that the tumour […]
This test relies on pharmacogenomics. This is the science of inherited variations in genes, how these inherited variations dictate a patient’s response to a drug, and the ways these variations can be used to predict whether a patient will have a good or bad response to a drug, or no response at all. ChemoSNiP tests […]
This test provides information about the efficacy of natural biological substances or extracts on circulating tumour cells. Onconomics Extracts focuses on testing using three methods: testing for the direct effect of an anti-cancer treatment, stimulating the immune system and inhibiting proliferative signals in the cancer cells that stimulate them to grow.
This test provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. Onconomics Plus RGCC is based on three methods: testing for the direct effect […]
This test provides information about the effect of specific anti-cancer drugs and targeted therapies on a single patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays.
This test provides information about the presence of circulating tumour cells, their concentration, and immunophenotype for specific types of malignancies. This test is a tailor-made test for certain cancers: such as breast cancer (for which we provide the Oncotrail RGCC for breast cancer) and prostate cancer (for which we provide Oncotrail RGCC for prostate cancer. […]
This test provides information about the presence of circulating tumour cells, and their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.
This test detects the presence of circulating tumour cells, and measures their concentration in the blood. As these cells that could lead to the recurrence of a cancer, this test is useful to detect relapse early, and as a follow-up tool.
Find out more about our latest research, trials and education days
UK scientists have discovered that liquid biopsy tests are 99% accurate at picking up crucial genetic mutations in patients with returning breast cancer. Researchers studying the potential for liquid biopsies have concluded that circulating tumour DNA (ctDNA) testing can provide an accurate genomic profile of advanced cancer, without the need for an invasive and potentially […]
The UK’s National Health Service (NHS) is to trial a liquid biopsy test that can identify up to 50 forms of cancer. Set to begin in 2021, the pilot project will assess how accurate and effective liquid biopsy testing is at diagnosing the disease. If successful, liquid biopsy testing could be rolled out across the […]
A US study of 3,000 cancer patients discovered that 13.5% had an inherited genetic mutation that caused their disease. In most cases, these mutations wouldn’t have been detected by clinicians using a standard guideline-based approach, leaving relatives unaware that they could be at an increased risk of developing cancer in the future. The discovery provides […]
Liquid biopsies have the potential to “substantially help to improve diagnosis” of breast cancer in women, a new study has found. Researchers writing in EBioMedicine (published by world-leading publisher The Lancet) found that “the clinical validity of liquid biopsy in the early breast cancer setting is more than evident.” Liquid biopsy techniques involve analysing a […]
Population-based screening for the BRCA genes that cause ovarian and breast cancer could save millions of lives a year, scientists have found. A new study, published in the journal Cancer, found that population-based genetic testing for BRCA 1 and BRCA 2 genes – where every woman over 30, regardless of risk-factor is screened – was […]
